



Fig. S1 Trial profile.

*Tumor biopsies were collected to conduct immunohistochemistry staining for triple-negative breast cancer subtyping and next-generation sequencing. Patients were assigned to one of seven parallel treatment arms based on their subtype and sequencing results. n, number.